Journal
JOURNAL OF THE AMERICAN MEDICAL INFORMATICS ASSOCIATION
Volume 28, Issue 6, Pages 1353-1355Publisher
OXFORD UNIV PRESS
DOI: 10.1093/jamia/ocab035
Keywords
artificial intelligence; bias; regulation; clinical decision support; reporting standards
Ask authors/readers for more resources
The FDA is considering permanently exempting certain medical device products from premarket notification requirements, including some AI-driven devices, which may have implications for the safety and effectiveness of the public.
The Food & Drug Administration (FDA) is considering the permanent exemption of premarket notification requirements for several Class I and II medical device products, including several artificial Intelligence (AI)- driven devices. The exemption is based on the need to rapidly more quickly disseminate devices to the public, estimated cost-savings, a lack of documented adverse events reported to the FDA's database. However, this ignores emerging issues related to Al-based devices, including utility, reproducibility and bias that may not only affect an individual but entire populations. We urge the FDA to reinforce the messaging on safety and effectiveness regulations of Al-based Software as a Medical Device products to better promote fair Al-driven clinical decision tools and for preventing harm to the patients we serve.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available